FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
	D.C.	20040

OTATERAENIT.	^ -	CHANGE	INI	DENIELOIAL	OWNEDGLUD
SIAIEMENI	OF	CHANGES	IN	BENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response.	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Graham G. Walmsley					2. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [OLMA]								telationship of eck all applica	able)	Perso	10% Ow	ner	
(Last) (First) (Middle) C/O LOGOS GLOBAL MANAGEMENT LP 1 LETTERMAN DRIVE, BLDG. D, STE D3-700					3. Date of Earliest Transaction (Month/Day/Year) 06/01/2020								Officer (give title Other (specify below) below)					
(Street) SAN FRANCIS			94129		4. If Amendment, Date of Original Filed (Month/Day/Year) 11/19/2020					6. I Lin	dividual or Joint/Group Filing (Check Applicable) X Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Tran		ansactio			3. Transaction Code (Instr. 3, 4)			d (A) or	5. Amoun	Form		n: Direct I or Indirect E nstr. 4) (7. Nature of ndirect Beneficial Dwnership					
							Code	v	Amount	(A) or (D)	Price	Transaction (Instr. 3 au	on(s) nd 4)			nstr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise (Instr. 3) Conversion Date (Month/Day/Year) A. Deemed Execution Date, if any (Month/Day/Year) Conversion Date (Month/Day/Year)		4. Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)				
				Code	v	(A)	(D)	Date Exercisabl		expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)			
Series B Convertible Preferred Stock	(1)	06/01/2020		P		339,578		(1)		(1)	Common Stock	339,578	\$4.7117	1,400,7	761	I	See Footnote ⁽²⁾	

Explanation of Responses:

- 1. The shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock are convertible into Common Stock on a 1:1 basis and have no expiration date. Immediately upon the closing of the Issuer's initial public offering, all shares of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock will be automatically converted into shares of Common Stock.
- 2. The shares are held by Logos Opportunities Fund I L.P. ("Logos Fund I"). Logos Opportunities GP, LLC ("Logos GP") is the general partner of Logos Fund I and the Reporting Person is a managing member of Logos GP. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

Remarks:

This amendment is being filed to correct the number of Series B Convertible Preferred Stock held in Column 9.

/s/ John B. Moriarty, Jr., Attorney-in-Fact

11/20/2020

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.